Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Treatment of respiratory virus infections

Yacine Abed, Guy Boivin *

Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Quebec City, Que., Canada

Received 5 December 2005; accepted 8 January 2006

Abstract

Respiratory viral infections (RVIs) can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions, such as pneumonia. RVIs constitute the most frequent reason for medical consultations in the world and they have a considerable impact on quality of life and productivity. Therefore, the prevention and control of RVIs remain major clinical goals.

Currently, there are approximately 200 known respiratory viruses that can be grouped into one family of DNA viruses (Adenoviridae) and four families of RNA viruses (Orthomyxoviridae, Paramyxoviridae, Picornaviridae and Coronaviridae). In this paper, we review the major respiratory viruses that cause diseases in humans, with an emphasis on current treatment options.

© 2006 Elsevier B.V. All rights reserved.

Keywords: Viral infections; Epidemic influenza; Respiratory viruses; Antivirals

Contents

0. Introduction ............................................................................................................... 2
1. Orthomyxoviridae ......................................................................................................... 2
  1.1. Treatment of influenza infections ..................................................................................... 3
    1.1.1. Adamantanes ............................................................................................... 3
    1.1.2. Neuraminidase inhibitors (NAIs) .............................................................................. 4
    1.1.3. Other NAIs ................................................................................................. 6
2. Paramyxoviridae .......................................................................................................... 6
  2.1. Human respiratory syncytial virus (HRSV) ................................................................. 6
    2.1.1. Treatment of HRSV infections .............................................................................. 7
  2.2. Parainfluenza viruses (HPIVs) ........................................................................................ 8
    2.2.1. Treatment of HPIV infections ................................................................................ 8
  2.3. Human metapneumovirus (HMPV) ............................................................................ 9
    2.3.1. Treatment of HMPV infections .............................................................................. 9
3. Picornaviridae ............................................................................................................. 9
  3.1. Treatment of picornavirus infections ............................................................................ 9
    3.1.1. Interferons .................................................................................................. 9
    3.1.2. Pleconaril ................................................................................................. 10
    3.1.3. BTA188 ................................................................................................... 10
    3.1.4. Soluble ICAM ............................................................................................. 10
    3.1.5. 3C protease inhibitors ...................................................................................... 10

* Corresponding author at: CHUQ-CHUL, Room RC-709, 2705 blvd Laval, Sainte-Foy, Que., Canada G1V 4G2. Tel.: +1 418 654 2705; fax: +1 418 654 2715.
E-mail address: Guy.Boivin@crchul.ulaval.ca (G. Boivin).

0166-3542/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.antiviral.2006.01.006
Respiratory viral infections (RVIs) are the most frequent reason for medical consultations in the world (Anzueto and Niederman, 2003). They can be associated with a wide range of clinical manifestations from self-limited infections of the upper respiratory tract to more devastating conditions affecting the lower respiratory tract, such as pneumonia. In addition, RVIs have a considerable impact on quality of life and productivity of the society. For example, in the United States alone, these infections are responsible for 20 million absences from work and 22 million absences from school every year (Brooks et al., 2004). Each year, consumers spend 2–3 billion dollars on a myriad of products marketed to treat cold symptoms, such as antihistamines, analgesics, antitussive and anti-inflammatory agents (Tentte, 2000).

Following the considerable research progress on respiratory viruses in the 60s, species of rhinoviruses, coronavirus, enteroviruses, adenoviruses, parainfluenza viruses and respiratry syncyntial viruses were added to influenza viruses as causes of respiratory tract infections. Recently identified respiratory viruses such as human metapneumovirus (Van den Hoogen et al., 2001; Boivin et al., 2002a); human parechovirus-3 (Ito et al., 2004; Boivin et al., 2005), and new human coronaviruses (HCoVs), such as the one associated with severe acute respiratory syndrome (SARS) (Ksiazek et al., 2003) as well as HCoV-NL (Fouchier et al., 2004) and HCoV-HKU1 (Woo et al., 2005a,b) are important additions to this list. Currently, there are approximately 200 known viruses that typically produce respiratory syndromes. They are grouped into five viral families including one family of DNA viruses (Adenoviridae) and four families of RNA viruses (Orthomyxoviridae, Paramyxoviridae, Picornaviridae and Coronaviridae) (Table 1). The purpose of this paper is to review the major respiratory viruses that cause diseases in humans, with an emphasis on current therapeutic options.

### 4. Coronaviridae

| 4.1. Treatment of SARS-CoV infections |
|--------------------------------------|
| 4.1.1. Ribavirin | 10 |
| 4.1.2. Protease inhibitors | 10 |
| 4.1.3. Fusion inhibitors | 11 |
| 4.1.4. Steroids | 11 |
| 4.1.5. siRNA | 11 |

### 5. Adenoviridae

| 5.1. Treatment of Ad infections |
|--------------------------------|
| 5.1.1. Ribavirin | 12 |
| 5.1.2. Cidofovir | 12 |

### 6. Conclusion

References

---

### 1. Orthomyxoviridae

Orthomyxoviruses are enveloped negative-sense RNA viruses containing 7 or 8 RNA segments which code for 9 or 11 proteins (Hayden and Palese, 2002). The RNA is protected by closely associated nucleoprotein forming a helical structure called the nucleocapsid (NC). Based on the NC and matrix (M1) antigens, influenza viruses are classified into three genera: influenza A, B, and C viruses. Influenza viruses contain two important surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which are responsible for virus attachment to host-cell receptors and virion release from infected cells, respectively. Antigenic differences in the HA and NA proteins provide further classification of influenza A viruses into 16 HA and 9 NA subtypes. All of these subtypes have been identified in birds whereas some are known to infect pigs, horses and whales (Hayden and Palese, 2002). During the past century, only 3 HA (H1, H2, H3) and 2 NA (N1, N2) subtypes have efficiently infected humans.

Influenza viruses are spread by respiratory droplets resulting in a spectrum of clinical responses ranging from mildly symptomatic infection to a primary viral pneumonia rapidly progressing to death (Lamb and Webster, 2001). Influenza A viruses are usually associated with a more severe outcome than B or C viruses. A typical influenza A syndrome consists of a tracheobronchitis with the additional involvement of small airways (Lamb and Webster, 2001). The incubation period averages 2...
days, whereas viral shedding in respiratory tract secretions generally lasts 3–6 days in immunocompetent adults. The onset of illness is usually abrupt with headache, chills, and dry cough followed by high fever, significant myalgias, malaise, and anorexia. More usual and benign complications of influenza include sinusitis, otitis media and bronchitis. More severe complications such as viral and/or bacterial pneumonia, as well as exacerbation of underlying illnesses, may also occur particularly in young children, the elderly, and subjects with cardiopulmonary diseases or immunosuppression (Wright and Webster, 2001).

Although annual immunization programs using the inactivated trivalent vaccine remain the most important means of reducing influenza-related morbidity and mortality, there are certain conditions where antiviral agents are warranted: (1) for the treatment and/or prevention of disease in individuals who are not vaccinated or do not mount an adequate immune response to the vaccine; (2) in years where there is a mismatch between the circulating and the vaccine viral strains; (3) in the advent of a new pandemic strain pending availability of an adequate vaccine.

1.1. Treatment of influenza infections

1.1.1. Adamantanes

1.1.1.1. Mechanism of action. Amantadine (1-adamantamine hydrochloride; Symmetrel) and its analogue, rimantadine (N-methyl-1-adamantanemethylamine; Flumadine), constitute the first class of antivirals licensed for influenza infections. These agents inhibit an early step in the influenza A virus replication cycle by interfering with the function of the viral M2 protein (Fig. 1). The latter acts as an ion channel through which the hydrogen ions pass into the interstices of the viral particle, resulting in the dissociation of the matrix protein (M1) from the ribonucleoprotein (RNP) complex. The RNP can then enter the cell nucleus and initiate replication (Martin and Helenius, 1991). Both amantadine and rimantadine are effective at low doses against various subtypes of influenza A viruses whereas they have no activity against influenza B viruses. In cell culture experiments, the concentration of amantadine that inhibits influenza A virus plaque formation by 50% (IC50) varies from 0.1 to 0.4 μg/ml (Hayden and Palese, 2002).

1.1.1.2. Pharmacokinetics. Amantadine and rimantadine are administered orally as tablets or syrup at doses of 5 mg/kg of body weight for children and up to 200 mg/day for adults (Moscona, 2005). These drugs are absorbed rapidly and nearly completely with peak plasma concentrations reached within 2 h for amantadine and 4 h for rimantadine (Couch, 2000). Amantadine and rimantadine are mostly metabolized and highly excreted in the urine, with amantadine half-life of about 15 and 30 h in young adults and elderly subjects, respectively, whereas rimantadine half-life averages 30 h in both groups (Couch, 2000).
1.1.1.3. Clinical efficacy. Both amantadine and rimantadine are effective for the prevention of influenza A infection and illness (Hayden and Palese, 2002). When used prophylactically, either drug can prevent about 50% of infections and 70–90% of illnesses (Couch, 2000). Demicheli et al. (2000) have estimated that the average effectiveness of amantadine and rimantadine for the prevention of confirmed influenza illness was 61% and 72%, respectively. The therapeutic use of these drugs has also been associated with a reduction in the duration of symptoms by approximately 1 day when administered within 48 h of onset of symptoms (Couch, 2000). However, these drugs have not been shown to prevent complications associated with influenza infections (Monto, 2003, Bridges et al., 2003).

1.1.1.4. Side effects. Amantadine causes central nervous system (CNS) symptoms such as anxiety, depression, and insomnia in about 10% of subjects, whereas CNS symptoms have been reported in only 2% of individuals treated with rimantadine (Couch, 2000). Besides CNS symptoms, both amantadine and rimantadine can cause transient gastrointestinal symptoms, including nausea and vomiting (Couch, 2000). However, these drugs have not been associated with a reduction in the duration of symptoms by 72%, respectively. The therapeutic use of these drugs has also been associated with a reduction in the duration of symptoms by approximately 1 day when administered within 48 h of onset of symptoms (Couch, 2000). However, these drugs have not been shown to prevent complications associated with influenza infections (Monto, 2003, Bridges et al., 2003).

1.1.1.4. Side effects. Amantadine causes central nervous system (CNS) symptoms such as anxiety, depression, and insomnia in about 10% of subjects, whereas CNS symptoms have been reported in only 2% of individuals treated with rimantadine (Couch, 2000). Besides CNS symptoms, both amantadine and rimantadine can cause transient gastrointestinal symptoms, including nausea and vomiting (Couch, 2000). However, these drugs have not been associated with a reduction in the duration of symptoms by 72%, respectively. The therapeutic use of these drugs has also been associated with a reduction in the duration of symptoms by approximately 1 day when administered within 48 h of onset of symptoms (Couch, 2000). However, these drugs have not been shown to prevent complications associated with influenza infections (Monto, 2003, Bridges et al., 2003).

1.1.1.5. Resistance to adamantanes. Despite the fact that naturally occurring amantadine-resistant influenza A viruses are rarely found, rates of resistance exceeding 30% and up to 80% have been reported after only a few days of therapy (Klimov et al., 1995; Shiraiishi et al., 2003; Hayden et al., 1991). Molecular characterization of amantadine-resistant influenza A variants has revealed that a single substitution at one of five codons (26, 27, 30, 31, and 34) in the transmembrane region of the M2 protein may confer drug resistance (Klimov et al., 1995; Masuda et al., 2000; Boivin et al., 2002b; Saito et al., 2003). A recent report showed that H3N2-infected individuals shed more amantadine-resistant variants than their H1N1-infected counterparts (Saito et al., 2003). Of note, the current avian influenza H5N1 virus (Z strain), which emerged in Southeast Asia, is resistant to amantadine (Li et al., 2004). This concern is further enhanced by the fact that adamantane-resistant mutant viruses were found to maintain good replicative capacities in vitro and were at least as virulent as wild-type (sensitive) viruses in animal models (Sweet et al., 1989). Nevertheless, adamantane-resistant influenza A viruses are transmissible in humans (Hayden et al., 1989).

1.1.2. Neuraminidase inhibitors (NAIs)

1.1.2.1. Mechanism of action. The NAIs target the active site of the NA enzyme, which is highly conserved in all influenza A and B viruses. NAIs inhibit the cleavage of the terminal sialic acid residues attached to viral glycoproteins and cellular glycolipids (Fig. 1), a process necessary for release of influenza virions from host cells and for spread of the virus throughout respiratory mucus (Palese and Combs, 1976). Zanamivir and oseltamivir have excellent in vitro activity against all nine NA subtypes of influenza A and against the NA of influenza B viruses (Mendel and Roberts, 1998). Notably, these drugs are effective against avian viruses of the H5N1 subtype, although higher doses and prolonged treatment with oseltamivir were required to achieve inhibition of such viruses in mice (Yen et al., 2005). The zanamivir IC50 values for clinical isolates vary widely using a plaque reduction assay (PRA) in Madin Darby canine kidney (MDCK) cells (2–16,000 nM), but fall in a much narrower range (0.64–7.9 nM) by directly testing the inhibition of NA activity using an enzymatic assay (Whitherell et al., 2003). Zanamivir exhibits better in vitro antiviral activity against influenza B viruses, whereas oseltamivir has lower IC50 values against influenza A isolates (Boivin and Goyette, 2002; Whitherell et al., 2003).

1.1.2.2. Pharmacokinetics. Zanamivir (Relenza) is commercially available as a drug powder for inhalation (Diskhaler). About 80% of a dose of zanamivir is deposited in the oropharynx, whereas 10–20% reaches the lungs (Cas et al., 1999a). Ten to 20% of the inhaled dose is bioavailable; however, the concentration of the drug in the respiratory tract is estimated to be >1000 times that of the IC50 value of influenza A and B viruses (Peng et al., 2000). Absorbed drug is excreted in the urine without metabolic changes (Cas et al., 1999b). Oseltamivir (Tamiflu) is available for oral administration (capsules or liquid suspension) as an ethyl ester prodrug which is converted to its active form (oseltamivir carboxylate) after ester hydrolysis in the gut (Kim et al., 1997). About 75% of the dose is widely distributed in the body, allowing the drug to be active outside the respiratory tract (Moscona, 2005). Oseltamivir carboxylate is excreted mainly through the kidneys; therefore, dosing must be reduced in patients with advanced renal insufficiency (creatinine clearance <30 ml/min) (Moscona, 2005).

1.1.2.3. Clinical efficacy. Both zanamivir and oseltamivir are effective for the prevention of influenza infections (Table 2). Zanamivir provided a reduction in incidence of laboratory-confirmed symptomatic influenza by 67% during seasonal prophylaxis in the community (Monto et al., 1999a) and by 79% during post-exposure prophylaxis in households (Hayden et al., 2000). Oseltamivir reduced the incidence of laboratory-confirmed influenza by 76% during seasonal prophylaxis in the community (Hayden et al., 1999) and by 92% in institutionalized elderly subjects (Peters et al., 2001). When used as post-exposure prophylaxis in households, oseltamivir was associated with a reduction in incidence of laboratory-confirmed influenza by 89% and 84% in individuals ≥12 years old and in number of households, respectively (Welliver et al., 2001). Effectiveness of oseltamivir for post-exposure prophylaxis in children ≥1 year old has also been demonstrated, although the drug is currently only approved for prophylaxis in children older than 13 years (Hayden et al., 2004). Zanamivir and oseltamivir are also effective for the treatment of influenza infections (Table 3). Zanamivir at a dose of 10 mg twice daily for 5 days started within 48 h of onset of symptoms reduced the duration of symptoms of naturally occurring influenza infections by 1–2.5 days in adults (Monto et al., 1999b; Hayden et al., 1997; The MIST Study Group, 1998; Makela et al., 2000; Boivin et al., 2000). In children 5–12 years old, zanamivir reduced duration of symptoms by 1.25 days (Hedrick et al., 2000). A meta-analysis of randomized,
respectively (Kaiser et al., 2003). In children (1–12 years old), the median time to alleviation of symptoms was reduced by 1.2 and 1.45 days, respectively (Nicholson et al., 2000; Aoki et al., 2003). In patients treated with either 75 mg (recommended dose) or 150 mg of oseltamivir b.i.d. for 5 days, the median duration of illness by 1.5 days and afforded reductions in cough, coryza and fever (Whitley et al., 2001). The incidence of antibiotic prescriptions and 1.25 days, respectively (Nicholson et al., 2000; Treanor et al., 2000; Aoki et al., 2003). In children (1–12 years old), oseltamivir treatment reduced the median duration of illness by 1.5 days and afforded reductions in cough, coryza and fever (Whitley et al., 2001). The incidence of antibiotic prescriptions was also significantly reduced in the oseltamivir group (31%) compared to the placebo group (41%). For maximal benefits, antiviral treatment must start as early as possible and within 48 h of the onset of symptoms. Indeed, for every 6 h reduction of oseltamivir treatment initiation time compared to symptom onset, median illness duration could be shortened by ∼10 h (Aoki et al., 2003). In United States of America, oseltamivir is approved for treatment of individuals ≥7 years (10 mg twice daily for 5 days) whereas zanamivir is licensed for treatment of persons ≥1 year (30–75 mg twice daily for 5 days) (Moscona, 2005).

### 1.1.2.4. Side effects.

Minor side effects have been reported in less than 5% of persons who were given zanamivir in clinical trials. They include transient upper respiratory and gastrointestinal symptoms (Moscona, 2005). Nevertheless, zanamivir should be used with caution in patients with chronic respiratory diseases, since it can cause bronchospasm and reductions in air flow (Couch, 2000). Oseltamivir has also a few side effects, such as transient nausea, vomiting and abdominal pain, which occur in about 10% of treated persons (Couch, 2000). Such side effects were also demonstrated that zanamivir conferred reduction in duration of symptoms by 2.5 days with a 43% reduction in complications in high-risk patients with confirmed influenza infection (Lalezari et al., 2001). Similarly, oseltamivir is effective in the treatment of naturally occurring influenza infections in adults (Nicholson et al., 2000; Treanor et al., 2000; Aoki et al., 2003). In patients treated with either 75 mg (recommended dose) or 150 mg of oseltamivir b.i.d. for 5 days, the median duration of illness could be shortened by 1.2 and 1.45 days, respectively (Nicholson et al., 2000). In adults and adolescents with a proven influenza illness, oseltamivir treatment reduced the incidence of influenza-related lower respiratory tract complications and antibiotic use by 55% and 26.7%, respectively (Kaiser et al., 2003). In children (1–12 years old), oseltamivir treatment reduced the median duration of illness by 1.5 days and afforded reductions in cough, coryza and fever (Whitley et al., 2001). The incidence of antibiotic prescriptions was also significantly reduced in the oseltamivir group (31%) compared to the placebo group (41%). For maximal benefits, antiviral treatment must start as early as possible and within 48 h of the onset of symptoms. Indeed, for every 6 h reduction of oseltamivir treatment initiation time compared to symptom onset, median illness duration could be shortened by ∼10 h (Aoki et al., 2003). In United States of America, oseltamivir is approved for treatment of individuals ≥7 years (10 mg twice daily for 5 days) whereas zanamivir is licensed for treatment of persons ≥1 year (30–75 mg twice daily for 5 days) (Moscona, 2005).

### Table 2

Selected trials of neuraminidase inhibitors for prevention of influenza infections

| Drug | Study population/setting | Reduction in incidence of laboratory-confirmed influenza | Reference |
|------|--------------------------|-------------------------------------------------------|-----------|
| Zanamivir | Healthy adults/seasonal prophylaxis in the community | 67%, 84% (flu with fever) | Monto et al. (1999a) |
| Zanamivir | Healthy adults/post-exposure prophylaxis (PEP) in households | 79% | Hayden et al. (2000) |
| Zanamivir | Individuals ≥12 years old/PEP in households | 69% | Cooper et al. (2003) |
| Zanamivir | Adults and children ≥1 year/PEP in households | 81% | Cooper et al. (2003) |
| Zanamivir | Elderly subjects (>80% vaccinated)/seasonal prophylaxis in institutional setting | 76%, 90% (flu with fever) | Hayden et al. (1999) |
| Oseltamivir | Healthy adults/seasonal prophylaxis in the community | 92% | Peters et al. (2001) |
| Oseltamivir | Adults with laboratory-confirmed influenza (meta-analysis) | 74% | Cooper et al. (2003) |
| Oseltamivir | Children (1–12 years) with laboratory-confirmed influenza | 1.2 | (75 mg), 1.45 days | Treanor et al. (2000) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 1.5 | | Cooper et al. (2003) |
| Zanamivir | Children (5–12 years) with laboratory-confirmed influenza (meta-analysis) | 2.0 | | Cooper et al. (2003) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 2.5 | | Lalezari et al. (2001) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 1.3 | | The MIST Study Group (1998) |
| Zanamivir | Children with laboratory-confirmed influenza (meta-analysis) | 1.25 | | Cooper et al. (2003) |
| Oseltamivir | Adults/PEP in households (meta-analysis) | 89% for individuals, 84% for households | Welliver et al. (2001) |
| Oseltamivir | Healthy adults/seasonal prophylaxis (meta-analysis) | 68% for individuals (41% when excluding patients positive at baseline), 58.5% for households (79% when excluding patients positive at baseline) | Hayden et al. (2004) |
| Oseltamivir | Healthy adults/seasonal prophylaxis (meta-analysis) | 74% | Cooper et al. (2003) |
| Oseltamivir | Adults/PEP in households (meta-analysis) | 90% | Cooper et al. (2003) |

### Table 3

Selected trials of neuraminidase inhibitors for treatment of influenza infections

| Drug | Study population | Reduction in the median time to alleviation of symptoms (days) | Reference |
|------|-----------------|-------------------------------------------------------------|-----------|
| Zanamivir | Healthy adults with laboratory-confirmed influenza | 1 | Monto et al. (1999a) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza | 1 | Hayden et al. (1997) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza | 1.5 | The MIST Study Group (1998) |
| Zanamivir | Children (5–12 years) with laboratory-confirmed influenza | 1.25 | Hedrick et al. (2000) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 1.25 | Cooper et al. (2003) |
| Zanamivir | Children with laboratory-confirmed influenza (meta-analysis) | 1 | Cooper et al. (2003) |
| Zanamivir | High-risk patients with laboratory-confirmed influenza (meta-analysis) | 2.0 | Cooper et al. (2003) |
| Zanamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 2.5 | Lalezari et al. (2001) |
| Oseltamivir | Adults/PEP in households (meta-analysis) | 1.3 | | The MIST Study Group (1998) |
| Oseltamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 1.25 | | Cooper et al. (2003) |
| Oseltamivir | Children (5–12 years) with laboratory-confirmed influenza (meta-analysis) | 1.5 | | Cooper et al. (2003) |
| Oseltamivir | Healthy adults with laboratory-confirmed influenza (meta-analysis) | 0.4 | | Cooper et al. (2003) |

**Note:** Treatment was initiated within 48 h of the onset of symptoms.
S, susceptible; R, resistant; I, intermediate.

| Virus                                      | NAI used for selection | NA mutation | Phenotype in NA inhibition assays using |
|--------------------------------------------|------------------------|-------------|-----------------------------------------|----------------------------------|
| A/Texas/36/91, A/New York/02/2001 (H1N1)  | Oseltamivir in humans   | H274Y       | S, R, R, R                              | Zanamivir: E119G R S S           |
| A/Huanan/50408/2005 (H5N1)                | Oseltamivir in humans   | H274Y       | S, R, ?                                  | Oseltamivir: E119V S R S         |
| A/Japan/57/2001, A/Turkey/Minnesota/833/80 (H4N2) | Oseltamivir in mice    | R292K       | R, R, R                                  | Zanamivir: E119V R R R I         |
| A/Texas/131/2002, A/Charlottesville/03/2004 (H3N2) | Oseltamivir in humans   | E119V       | S, R, S                                  | Oseltamivir: E119G R S S S       |
| A/Texas/36/91, A/New York/02/2001 (H1N1)  | Oseltamivir in humans   | E119G       | R, S, S                                  | Oseltamivir: E119A R I S S       |
| B/Rochester/02/2001                       | Oseltamivir in humans   | R152K       | R, R, R                                  | Zanamivir: E119D R S R R         |
| B/Memphis/20/1996                        | Oseltamivir in humans   | D198N       | R, R, S                                  | Oseltamivir: E119D R S R R       |

*Numbers indicate the position of the substituted residue in the NA amino acid sequence (N2 numbering).

Resistance to NAIs: In vitro studies have shown that numerous (12–20) viral passages in the presence of the drug are required to select resistant variants. Resistance to NAIs can result from mutations in the active site of the NA enzyme, associated or not with aa changes in or near the receptor binding site of the HA protein. The latter changes are thought to reduce viral dependency on NA activity. However, the clinical consequences of HA mutations on development of NAI resistance have not been demonstrated in contrast to NA mutations (Abed et al., 2002; Gubareva et al., 2001). NA mutations associated with NAI resistance are subtype-specific and drug-specific and involve both catalytic and framework residues (Table 4). Mutations at codon 292 (Arg292Lys) and 119 (Glu119Val) predominate in H3N2 viruses, whereas a His274Tyr mutation (N2 numbering) is the most frequent in H1N1 viruses (Abed et al., 2004; Whitley et al., 2001; Wang et al., 2002; Weinstock et al., 2003). Of note, the last mutation has been reported in H5N1 viruses isolated in Asia (Le et al., 2005; de Jong et al., 2005). Unlike amantadine-resistant variants, NAI-resistant influenza viruses were infrequent in clinical trials with estimated rates of resistance varying from 0.4% to 1% in the adult population and from 4% to 8% in children (Roberts, 2001). However, higher rates (18%) of oseltamivir resistance were reported in a recent treatment study of Japanese children (Kiso et al., 2004). Most, but probably not all, NAI-resistant variants seem to be compromised with regard to infectivity and transmissibility in mice (Ives et al., 2002) and ferrets (Herlocher et al., 2002). So far, resistance to zanamivir has been extremely infrequent, with one case reported from an immunocompromised child infected with influenza B (Gubareva et al., 1998). Whether this lower rate of resistance is due to intrinsic drug properties or lower use of this compound compared to oseltamivir should be clarified.

Other NAI: Besides zanamivir and oseltamivir, other compounds that target the NA enzyme of influenza viruses have been developed, although they are not commercially available. Peramivir, an orally bioavailable cyclopentane compound, is a potent NA inhibitor in vitro and in vivo (Sidwell and Smee, 2002). A-315675, a pyrrolidine-based compound, also demonstrated in vitro activity against influenza A (N1, N2, and N9 subtypes) and influenza B viruses which was similar to that of zanamivir and oseltamivir (Hanessian et al., 2002). Zanamivir derivative compounds containing different side-chains could also be considered as possible anti-influenza agents (De Clercq, 2002). The efficacy of the new NAIs against influenza A and B mutants is summarized in Table 4. Finally, ribavirin (discussed below) has in vitro activity against influenza viruses (Couch, 2000). In addition, it demonstrated high efficacy in preventing death and reducing lung virus titers in mice infected with influenza A or B viruses (Sidwell et al., 2005).

2. Paramyxoviridae

This viral family contains some of the most important respiratory viruses which cause epidemics of major medical interest. Paramyxoviruses are single-stranded negative-sense RNA viruses that are divided into two subfamilies (Fig. 2A). Paramyxoviruses include important viruses associated with upper and lower respiratory tract infections in humans i.e. human respiratory syncyctial virus (HRSV), human parainfluenza viruses (HPIV), and human metapneumovirus (HMPV). Unlike orthomyxoviruses, the RNA genome of paramyxoviruses is not segmented and encodes several subgenomic messenger RNA (mRNAs). For HRSV, there are 10 subgenomic mRNAs which are translated into 11 proteins, including 4 nucleocapsid proteins (N, P, L and M2-1), 3 transmembrane glycoproteins (F, G and SH), 2 non-structural proteins (NS1 and NS2), a matrix M protein and a RNA regulatory factor M2-2. Compared to HRSV, HMPV has no NS proteins whereas HPIVs possess a hemagglutinin-neuraminidase (HN) protein instead of the G protein with no NS, M2 and SH proteins (Fig. 2B).

2.1. Human respiratory syncytial virus (HRSV)

HRSV is a major cause of lower respiratory tract disease in premature babies (<35 months of gestation), infants less than...
6 months old, and elderly institutionalized subjects (Welliver, 2003; Greenough, 2002). The outcome of HRSV infection usually involves mild upper respiratory tract infections; however, more severe conditions, such as pneumonia and bronchiolitis occur in 25–40% of children (Meissner, 2003). Approximately 1% of HRSV-infected infants require hospitalization (Greenough, 2002). Each year, in the US, pediatric HRSV infections are associated with 50–90% of hospitalizations attributable to bronchiolitis and 20–50% of those attributable to pneumonia (Ogra, 2004). In the Northern Hemisphere, and in particular in the US, HRSV circulates predominantly during winter months and accounts for approximately 90,000 hospitalizations and 4000–17,000 deaths annually (Ogra, 2004; Thompson et al., 2003). There are currently no approved vaccines for HRSV despite considerable work in this area.

2.1.1. Treatment of HRSV infections

2.1.1.1. Ribavirin. Ribavirin (ViraAze: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a nucleoside analogue which is currently licensed for treatment of severe HRSV disease in high-risk infants (Brooks et al., 2004). This drug has a broad spectrum of activity against DNA and RNA viruses (Balfour, 1999). Ribavirin inhibits viral replication by several mechanisms, including inhibition of viral polymerase, inhibition of 5′ cap formation of mRNA, and inhibition of IMP dehydrogenase leading to a decrease of intracellular GTP concentrations (Zhao et al., 2000). Therefore the HR1/HR2 region seems to be a suitable target for the development of anti-HRSV agents. Recombinant HR1 and HR2 proteins expressed in E. coli showed a strong inhibitory effect on HRSV fusion with EC50 values of 1.68 and 2.93 μM, respectively (Wang et al., 2003). Recently, several small molecules with potent inhibitory effects on HRSV fusion have been identified. The triphenyl compound VP-14637 (ViroPharma) and the benzimidazole analogue JNJ408068 (Johnson and Johnson) are small molecules that...
interacting simultaneously with both HR1 and HR2 (Douglas et al., 2005). In a cell fusion assay, the IC\textsubscript{50} values of the same agents were 5.4 and 0.9 nM, respectively. The characterization of drug-resistant HRSV variants selected in vitro in presence of such inhibitors revealed amino acid changes in the interaction domain between HR1 and HR2 (Lys\textsubscript{399}Ile and Thr\textsubscript{400}Ala) (Douglas et al., 2005). Further in vitro studies showed that substitutions at residues 486–488, which are involved in direct contact with the bound inhibitor, could be responsible for the resistance phenotype (Douglas et al., 2005).

The polynuclear aromatic compound RFI-641 (Wyeth) has also potent anti-HRSV activity by blocking two viral F glycoprotein-mediated fusion events, including fusion of the virion envelope with the cellular plasma membrane and syncytium formation (Huntley et al., 2002). In vitro, RFI-641 inhibited HRSV A and B replication with average IC\textsubscript{50} values ranging from 0.018 to 0.055 μg/ml (Huntley et al., 2002). In addition, in an African green monkey model, prophylactic administration of RFI-641 resulted in a reduction in virus lung titers by ≥1.5 log within 3–10 days after HRSV challenge.

2.1.1.3. Antisense oligodeoxynucleotides. Antisense oligodeoxynucleotides (ODNs) are short (18–25 nucleotides) single-stranded molecules designed to inhibit RNA expression by annealing to complementary regions of the targeted mRNA. The newly formed RNA–DNA hybrid attracts endogenous ribonuclease H (RNase H) which cleaves the RNA portion of the hybrid (Crooke, 1992). This results in transcript degradation and/or prevents translation into proteins. A phosphorothioate ODN targeting HRSV repetitive intergenic sites has shown potent in vitro activity (Jairath et al., 1997).

2.1.1.4. Immune prophylactic agents. Two immune prophylactic agents have been approved for the prevention of HRSV disease. RespiGam is an intravenous polyclonal immune globulin enriched in neutralizing antibodies against HRSV which was recommended for the prevention of serious HRSV disease in high-risk infants. RespiGam reduced hospitalizations, hospital stay and total HRSV-related intensive care unit days by 41%, 53%, and 44%, respectively (Maggon and Barik, 2004). However, this product requires large volume infusion and its availability is currently limited.

Palivizumab (Synagis) is a monoclonal antibody composed of human (95%) and murine (5%) antibody sequences that is directed against the HRSV fusion (F) glycoprotein (Meissner, 2003; Johnson et al., 1997). Palivizumab is 50–100 times more potent than RespiGam and was approved by the US Food and Drug Administration (FDA) in 1998 for prevention of serious lower respiratory tract infections caused by HRSV. Palivizumab is recommended during the HRSV season (monthly intramuscular injection) for premature babies (≤32 weeks of gestation) and infants younger than 2 years of age with chronic lung disease or congenital heart disease. In a phase III clinical study involving 1502 high-risk infants, palivizumab reduced the incidence of hospitalization by 55% (The IMpact-RSV Study Group, 1998). Another double-blind, randomized, placebo-controlled study in 1287 children with congenital heart disease showed a 45% reduction in hospitalization in the treated group (Feltes et al., 2003). On the other hand, palivizumab did not seem to provide direct cost savings related to hospitalization or ambulatory care in infants who were born between 32 and 35 weeks of estimated gestational age (Wegner et al., 2004).

2.1.1.5. Steroids. A possible effect of glucocorticoid therapy for improving pulmonary inflammatory response after HRSV infection has been suggested (Vivoejc and Mills, 2001). A meta-analysis of six randomized controlled trials of systemic corticosteroid use in bronchiolitis showed that the duration of symptoms and length of hospital stay were significantly reduced by corticosteroid treatment (Garrison et al., 2006). However, a subsequent randomized, double-blind, placebo-controlled trial, demonstrated that dexamethasone impaired the decline of HRSV in the lower respiratory tract of infants with severe HRSV disease and was not associated with improvement of clinical outcomes (Buckingham et al., 2002).

2.2. Parainfluenza viruses (HPIVs)

Four distinct serotypes of human parainfluenza viruses have been described (Henrickson, 2003). These viruses can cause upper respiratory tract diseases in individuals of all age groups, although young children between 6 months and 3 years present more severe diseases (Henrickson, 2003). In the US, HPIVs account for approximately 33% of lower respiratory tract infections in children younger than 5 years (Denny and Clyde, 1986; Glezen et al., 1984). HPIV-1 and -2 have been reported to cause disease in the fall months of alternate years (Knott et al., 1994; Reed et al., 1997) whereas HPIV-3 appears to be endemic during most months of the year. HPIVs have been associated with laryngotracheobronchitis or croup (mainly HPIV-1), bronchiolitis and pneumonia (Henrickson, 2003).

At the present time, there exists no licensed HPIV vaccine, although recombinant and live-attenuated HPIV-3 vaccines, combined or not with HRSV glycoproteins, can induce satisfactory immune responses (Belshie et al., 2004).

2.2.1. Treatment of HPIV infections

Currently, there are no antivirals approved for the treatment of HPIV infections, although several compounds have demonstrated in vitro and/or in vivo activity against these viruses (Henrickson, 2003).

2.2.1.1. Ribavirin. Ribavirin exhibits in vitro antiviral activity against HPIVs (Browne, 1981). In plaque inhibition experiments, the drug reduced HPIV-1 and -2 plaque formation by 50% at a concentration of approximately 10 and 12 μg/ml, respectively (Browne, 1981). Aerosolized and oral ribavirin were also associated with reduction in HPIV shedding and clinical improvement in infected immunocompromised patients (Chakrabarti et al., 2001; Malinowski and Hostoffer, 2001).
2.2.1.2. Other antivirals and immunomodulators. The Hu of HPIV is responsible for virus binding to the host cell and for promoting F-protein-mediated fusion. In addition, it facilitates the spread of infection through its NA activity which cleaves the receptors and thus prevents virus aggregation (Hennickson, 2003). Zanamivir inhibits the NA of HPIV-3 with an IC50 value of 250 μM in NA assays (Greenard et al., 2000). Of note, the drug is approximately (100,000 times) less active against HPIV-3 compared to influenza viruses.

Two novel HPIV inhibitors (BCX2798 and BCX2855), which target the HN protein, have demonstrated potent in vitro activity against HPIV-1, -2, and -3 in LLC-MK2 cells with IC50 values of 0.1–0.9 μM in HA inhibition assays and 0.02–20 μM in NA inhibition assays (Alymova et al., 2004). In addition, these agents were associated with significant reduction in viral lung titers and protection from death in a mouse model of infection with a recombinant HPIV-1 virus. Also, some peptides have shown a potent inhibitory effect on HPIV-induced syncytium formation by targeting a specific domain of the F protein, which may provide a useful antiviral approach for severe HPIV infections (Gosh and Shay, 1998; Lambert et al., 1996).

Oral or parenteral steroids also appear to improve croup symptoms associated with moderate to severe HPIV infections (Somani and Evans, 2001). High-titer pooled immunoglobulins may also reduce lower respiratory tract infections due to HPIV (The PREVENT Study Group, 1997). Finally, combined immunotherapy and steroids was also shown to reduce pulmonary virus titers and inflammation in a cotton rat model (Prince and Porter, 1996). This strategy could constitute a therapeutic option for patients with severe HPIV disease until effective vaccines and antivirals are available.

2.3. Human metapneumovirus (HMPV)

Human metapneumovirus (HMPV) was first identified in 2001 from respiratory tract secretions of Dutch children with bronchiolitis (Van den Hoogen et al., 2001). HMPV can cause severe respiratory diseases, most particularly in young children, elderly subjects and immunocompromised hosts (Boivin et al., 2002a). The spectrum of disease and the epidemiology of HMPV resemble that of HRSV, including upper respiratory tract and lower respiratory tract illnesses i.e. cold and influenza-like illnesses, bronchiolitis, croup, pneumonia, and exacerbation of asthma and chronic obstructive pulmonary disease (Hamelin et al., 2004, 2006). In several pediatric studies, HMPV was found to be the second or third cause of hospitalizations in young children after HRV and possibly influenza (Savolainen et al., 2003). This genus includes more than 100 serotypes which are divided into two groups on the basis of their cellular receptors. The majority of rhinoviruses (91 serotypes) use the intracellular adhesion molecule 1 (ICAM-1) as their cell receptor for virus attachment, whereas the remaining serotypes use the low density lipoprotein (LDL) receptor (Mackel, 1993). In temperate climates, HRV infections can be observed throughout the year although there are peaks of activity during the fall and spring seasons (Makela et al., 1998). Besides the common cold, HRVs can cause acute otitis media, lower respiratory tract infections including pneumonia, wheezing in children and exacerbations of asthma and chronic obstructive pulmonary disease (COPD) in adults (Savolainen et al., 2003). Enteroviruses (echo and coxsackieviruses) and parechoviruses have been associated with numerous clinical syndromes including respiratory tract infections. There are no vaccines or specific immunoglobulins against the respiratory picornaviruses.

3. Picornaviridae

Picornaviruses constitute a diverse family of non-enveloped single-stranded positive-sense RNA viruses whose genome encodes a single polyprotein of 2100–2400 aa (Mackie, 2003). Three genera within this family (Rhinovirus, Enterovirus, and Parechovirus) can cause respiratory tract infections in humans. Human rhinoviruses (HRVs) are the most frequent cause of mild upper respiratory tract infections i.e. common colds (Makela et al., 1998, Savolainen et al., 2003). This genus includes more than 100 serotypes which are divided into two groups on the basis of their cellular receptors. The majority of rhinoviruses (91 serotypes) use the intracellular adhesion molecule 1 (ICAM-1) as their cell receptor for virus attachment, whereas the remaining serotypes use the low density lipoprotein (LDL) receptor (Mackie, 1993). In temperate climates, HRV infections can be observed throughout the year although there are peaks of activity during the fall and spring seasons (Makela et al., 1998). Besides the common cold, HRVs can cause acute otitis media, lower respiratory tract infections including pneumonia, wheezing in children and exacerbations of asthma and chronic obstructive pulmonary disease (COPD) in adults (Savolainen et al., 2003). Enteroviruses (echo and coxsackieviruses) and parechoviruses have been associated with numerous clinical syndromes including respiratory tract infections. There are no vaccines or specific immunoglobulins against the respiratory picornaviruses.

3.1. Treatment of picornavirus infections

3.1.1. Interferons

Interferons are glycoproteins that induce a number of antiviral, antiproliferative and immunological effects which, collectively, affect host-cell susceptibility to picornavirus infections (Rotbart et al., 1998). In conjunction with double-stranded RNA, interferons induce the expression of proteins, some of which mediate an antiviral activity. Interferons may also contribute with humoral antibodies and macrophages to the elimination of picornavirus infections (Balfour, 1999). Commercial preparations of interferon alpha are not orally bioavailable and need to be given by intramuscular or subcutaneous injections. Intranasal interferon α-2b was found to be active during clinical prophylactic studies of HRV infections, but has not demonstrated benefits in the treatment of established infection (McKinlay, 2001). Furthermore, nasal irritations and bleeding are major side effects that limit its use (Rotbart, 2000).
3.1.2. Pleconaril

Pleconaril (3-[3,5-dimethyl-4-((3-methyl-5-oxazolyl)-propyl)-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole), ViroPharma Inc., is an orally bioavailable anti-picornaviral agent (Pevear et al., 1999). It acts by integrating into the cavity of the viral capsid to inhibit its uncoating, thus blocking attachment to host-cell receptors and inhibiting viral replication (Pevear et al., 1999). Pleconaril demonstrated a potent broad spectrum activity against 93 of the 101 HRV serotypes and 45 of 55 culturable enterovirus serotypes (McKinlay, 2001). Pleconaril exhibited a median IC50 value of 0.07 \( \mu g/ml \) when tested against 5 selected HRV serotypes and 46 clinical HRV isolates (Kaiser et al., 2000). Pharmacokinetic studies in adults and children have shown that plasma concentrations were above the drug concentration that inhibits >90% of HRVs in vitro after oral administration (Pevear et al., 1999). In clinical trials, pleconaril conferred reductions in symptom severity and duration in individuals with naturally occurring colds (Isom et al., 2002). A recent study has shown that the clinical benefit correlated with drug susceptibility of the baseline virus isolate (Pevear et al., 2005). Pleconaril-treated subjects infected with highly susceptible viruses (IC50 \( \leq 0.38 \mu g/ml \)) experienced a median reduction in symptom duration of 1.9-3.9 days compared with that for the placebo-treated subjects. By contrast, subjects whose baseline virus isolate susceptibility was >0.38 \( \mu g/ml \) did not benefit from pleconaril treatment. During a 6-week prophylactic study on picornavirus respiratory infections, pleconaril was associated with an increase in menstrual irregularities. Subsequently, concerns have been raised that this drug might increase the metabolism and reduce the efficacy of some hormonal contraceptives and drugs used to treat HIV (HSV, 2005). As a result, pleconaril was not licensed by the FDA. An intranasal formulation of the drug is under investigation.

3.1.3. BTA188

BTA188 (Biota Inc.), another capsid-function inhibitor, has shown potent antiviral activity against 87 selected HRV serotypes, with a median IC50 value of 0.01 \( \mu g/ml \) (Hayden et al., 2001). BTA188 was also effective against all tested clinical HRV isolates \( n = 40 \) with a median IC50 value of 0.004 \( \mu g/ml \). This agent had a high bioavailability when evaluated in rodents and dogs, with accumulation in nasal tissue (Hayden et al., 2001). In dogs, mean concentrations of BTA188 in the nasal epithelium 24 h after dosing were 25 times higher than plasma concentrations and significantly higher than HRV IC50 values.

3.1.4. Soluble ICAM

Recombinant soluble ICAM-1 (Tremacamra, Boehringer Mannheim) binds competitively to the viral receptor of HRV in vitro, thus preventing attachment and subsequent replication (Shigeta, 1998). Moreover, in a randomized clinical trial of experimentally infected volunteers, this agent had a significant impact on the total symptom score (reduced by 45%), the proportion of subjects with clinical colds (reduced by 23%) and the total nasal mucus weight (reduced by 56%) (Turner et al., 1999). In addition, this antiviral appeared to be well tolerated.

3.1.5. 3C protease inhibitors

The 3C protein of picornaviruses is a protease which cleaves viral precursor polypeptide into structural proteins and enzymes which are essential for viral replication (Rothbard, 2000). AG7088 (Ruprintrivir, Agouron Pharmaceuticals, Inc.) is a potent inhibitor of HRV 3C protease. In vitro, it efficiently inhibited all 48 HRV serotypes tested with a mean IC50 value of 0.023 \( \mu M \) (range: 0.003–0.081 \( \mu M \)) (Patrick et al., 1999). In prophylactic studies, AG7088 reduced the incidence of colds, total symptom scores, respiratory symptoms and nasal discharge (Kaiser et al., 2000). Moreover, ruprintrivir provided reduction in total and respiratory symptoms by 2–3 days in subjects who started treatment within 24 h of onset of respiratory symptoms (Schmidt et al., 2001). Mild nausea and taste disturbance are common adverse effects (Munoz et al., 2000). On the other hand, the intranasal spray of ruprintrivir seemed to be well tolerated, with blood-tinged mucus and nasal irritation being the most common side effects (Hayden et al., 2003).

4. Coronaviridae

Coronaviruses were first isolated 40 years ago in organ cultures of human embryonic trachea and nasal epithelium and in primary human kidney cell cultures (Tyrrell and Byng, 1965). These viruses have a single-stranded positive-sense RNA genome of approximately 30 kb, which is considered to be the largest known autonomously replicating RNA (Thiel et al., 2001). About two-thirds of the genome encodes proteins involved in the replication and transcription of the viral RNA. There are three groups of coronaviruses that include several animal viruses and now five human viruses (Fig. 3). The human coronaviruses (HCoVs) OC43 and 229E are considered to be the second cause of the common cold after HRVs accounting for approximately 35% of mild upper respiratory infections in adults (Falsey et al., 2002). The virus responsible for the severe acute respiratory syndrome (SARS) outbreak between 2002 and 2003 was identified as a new coronavirus (SARS-CoV), which led to more than 8000 infections and 800 deaths in 26 countries (Ksiazek et al., 2003; Peiris et al., 2003). Clinically, SARS is characterized by systemic symptoms such as fever and myalgia followed by respiratory symptoms, including non-productive cough and dyspnea. Approximately 15% of cases deteriorate and require mechanical ventilation due to development of acute respiratory distress syndrome (ARDS) (Tsuo et al., 2003). More recently, HCoV-NL and HCoV-HKU1 have been associated with small numbers of cases of bronchiolitis and pneumonitis in humans (Fouchier et al., 2004; Woo et al., 2005a,b). There are currently no approved vaccines or specific immunoglobulins for the prevention of human coronaviruses although several groups are working on the development of effective vaccines using different approaches (Zhu, 2004).

4.1. Treatment of SARS-CoV infections

At the time of the SARS outbreak, no specific treatment was shown to prevent disease progression. However, research in that field has been intensified resulting in certain promising therapeutically...
Fig. 3. Classification of human and animal coronaviruses.

4.1. Ribavirin

Several small clinical studies have assessed the effectiveness of ribavirin against SARS-CoV. However, none of them clearly demonstrated its clinical efficacy (Groneberg et al., 2005). Furthermore, the drug is not active against SARS-CoV in vitro (Chen et al., 2004). In addition, Knowles et al. (2003) reported common adverse effects in individuals treated with high-dose ribavirin therapy for suspected or probable SARS, i.e. haemolytic anemia, hypocalcemia and hypomagnesemia reported in 61%, 58% and 46% of cases, respectively.

4.1.2. Protease inhibitors

The combination of HIV protease inhibitors such as lopinavir and ritonavir (Kaletra, Abbott Laboratories) could be potentially useful for the treatment of SARS because these agents have shown antiviral activity against SARS-CoV in vitro (Chen et al., 2004). In addition, Knowles et al. (2003) reported a significant reduction in the intubation and mortality rates (Chen et al., 2004). Chu et al. (2004) also evaluated lopinavir/ritonavir treatment compared with historic controls; all patients were also treated with ribavirin and steroids. Development of ARDS or death within 21 days were significantly lower in the lopinavir/ritonavir group compared to historic controls. Nosocomial infections were also reduced in the active group. Other protease inhibitors may be considered for the treatment of SARS because of their in vitro activity against SARS-CoV. These include nelfinavir, Calpain inhibitor III (Z-Val-Phe-Ala-CHO) and Calpain inhibitor IV (Val-Leu-CHO) (Yamamoto et al., 2004).

4.1.3. Fusion inhibitors

Fusion inhibitors are promising candidates for the treatment of SARS. It was postulated that the heptad region in the spike protein of SARS-CoV is involved in the mechanism mediating fusion between the virus and host-cell membranes (Liu et al., 2004). By analogy with the heptad regions 1 and 2 of the HIV-1 gp41 protein which provided the basis for anti-HIV fusion inhibitors, one peptide (CP1) within the heptad region 1 of the spike protein of SARS-CoV specifically inhibited viral replication in vitro (Liu et al., 2004).

5. Adenoviridae

Adenoviruses (Ads) are non-enveloped double-stranded DNA viruses that were first observed in human adenoid tissues in 1953. Fifty-one serotypes of human Ads have been classified into six groups (A–F) based on their biological characteristics, tumorigenicity, and DNA homology. Despite their multiorgan tropism, some types of Ads have a predilection for the respiratory tract and can cause a wide range of respiratory symptoms, including coryza, pharyngitis, tonsillitis, bronchitis, and pneumonia. Ads belonging to subgroups B (Ad3, 7, 14, 16, 21, 34, 35), C (Ad1, 2, 5, 6), and E (Ad4) account for up to 80% of
respiratory tract infections in young children (Russskanen et al., 1985). Ad4 and Ad7 are also significant causes of acute respiratory diseases in military recruits (Wadell, 1984; Erdman et al., 2002) and these serotypes were part of a live adenovirus vaccine. Ads were not found to be associated with the seasonality observed with most other respiratory viruses although they can cause sporadic outbreaks of disease. In general, Ad infections are mild or self-limited and resolve within 2 weeks without long-term complications. However, Ads constitute an important cause of mortality and morbidity in immunocompromised children and in neonates (Munoz et al., 1997; Azbug and Levin, 1991). Adenovirus pneumonia is associated with mortality rates as high as 60% in bone marrow transplant recipients (Hierholzer, 1992). Despite the fact that live, enteric-coated oral vaccines developed for Ad4 and Ad7 significantly lowered Ad morbidity by 95–99%, their production was discontinued in 1996. However, the U.S. Department of Defense recently awarded a contract to Barr Laboratories, Inc. to resume production of such vaccine (Blasiole et al., 2004).

5.1. Treatment of Ad infections

There are no approved therapeutic agents against Ad infections. However, some broad spectrum antivirals have been used in the treatment of severe Ad infections in immunocompromised hosts.

5.1.1. Ribavirin

Interferon (IV) ribavirin has shown some apparent success in the treatment of Ad disease in children including stem cell transplant (SCT) recipients with pneumonia (Howard et al., 1999), bone marrow transplant (BMT) recipients with gastroenteritis (Kapelushnik et al., 1995) and leukemic children with disseminated disease (McCarthy et al., 1995) although most reports are anecdotal or small series of cases. The most common adverse effect of IV ribavirin is a reversible mild anemia which is rarely symptomatic.

5.1.2. Cidofovir

Cidofovir, a broad spectrum cytosine nucleotide analogue, has shown some efficacy in treating symptomatic Ad-associated disease in immunocompromised children and adults (Ribaudo et al., 1999; Bordignon et al., 2001). In a study on 22 SCT patients (aged from 1 to 9 years), 2 of 3 patients treated with cidofovir recovered compared to 3 of 13 patients treated with ribavirin (Bordignon et al., 2001). However, the clinical use of IV cidofovir has been limited by its nephrotoxicity.

6. Conclusion

The prevention and control of respiratory viral infections remain major clinical goals because of their impact on the society in terms of health, quality of life and economy. With the notable exception of influenza viruses, there are no approved vaccines for the prevention of most respiratory viral infections despite continual efforts in this field. However, the immunoprophylactic agents RespriGam and Synagis constitute an effective strategy for the prevention of severe HRSV infections in premature and at-risk infants. Similarly, with the exception of antiviral agents, including adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir), there are no other licensed antivirals against the large variety of clinically important respiratory viruses such as HPIV, HRV, and Ads. Although ribavirin has been approved for the treatment of HRSV infection, its clinical use has been limited by its side effects combined to its minor clinical efficacy. Because most respiratory viral infections are self-limited and due to the lack of rapid point-of-care diagnostic methods, the commercialization of antiviral agents against respiratory viruses represents an important challenge. Nevertheless, numerous antiviral agents have shown potent in vitro and in vivo activities against different families of respiratory viruses and merit additional studies.

References

Abed, Y., Bourgault, A.M., Fenton, R.J., Morley, P.I., Tisdale, M., Boivin, G., 2002. Characterization of two influenza A: H1N2 viruses with reduced susceptibility to neuraminidase inhibitors from untreated patients due to mutations in the hemagglutinin gene. J. Infect. Dis. 186, 1074–1080.

Abed, Y., Goyette, N., Boivin, G., 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9, 577–581.

Abed, Y., Goyette, N., Boivin, G., 2005. Generation and characterization of recombinant influenza A/H1N1 viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 49, 556–559.

Alyounis, I.V., Taylor, G., Takimoto, T., Lin, T.H., Chaud, P., Babu, Y.S., Li, C., Xiong, X., Potumer, A., 2004. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2796 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48, 1495–1502.

Anzueto, A., Niederman, M.S., 2003. Diagnosis and treatment of rhinovirus respiratory infections. Chest 123, 1664–1672.

Aoki, F.Y., Macleod, M.D., Piggott, P., Carewisisi, O., Elsawi, A., Wat, C., Griffiths, M., Wadberg, E., Ward, P. The IMPACT Study Group, 2003. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 125–129.

Azbug, M.J., Levin, M.I., 1991. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 87, 890–896.

Ballou, H.R., 1999. Antiviral drugs. New Engl. J. Med. 340, 1255–1268.

Belisle, R.B., Newman, F.K., Anderson, E.L., Wright, P.F., Karon, R.A., Tollefson, S., 2004. Evaluation of combined live attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190, 2013–2096.

Biachcerei, S., Pan, Q.N., Siaudandopoulos, M.H., Murphy, B.R., Collins, B.L., Buchholz, U.J., 2005. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes such as a nonessential accessory protein and identifies vaccine candidates. J. Virol. 79, 12608–12613.

Blasiole, D.A., Metzger, D., Darrn, L.T., Ryan, M.A.K., Wu, J., Wills, C., Le, C.T., Freed, N.E., Hansen, C.J., Gog, C.O., Russell, R.L., 2004. Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults. J. Clin. Microbiol. 42, 1686–1693.

Boivin, G., Goyette, N., Hardy, I., Aoki, F., Wagner, A., Trottier, S., 2000. A reverse genetics study of resistance to neuraminidase inhibitors from untreated patients due to mutations in the hemagglutinin gene. J. Infect. Dis. 186, 1330–1334.
Denny, F.W., Clyde Jr., W.A., 1986. Acute lower respiratory infections in children. J. Pediatr. 108, 635–646.

Boivin, G., Yusuf, A., 1993. ESSENCE: a potent inhibitor of influenza neuraminidase. Antimicrob. Agents Chemother. 37, 554–559.

Boivin, G., Yusuf, A., 1997. ESSENCE: a potent inhibitor of influenza neuraminidase. Antimicrob. Agents Chemother. 41, 554–559.

Boulanger, D., Boucher, F., 2005. Human parechovirus-3 and neonatal infections. Clin. Infect. Dis. 41, 498–502.

Bouwman, M.J., Sasadeusz, J.J., Tannock, G.A., 2004. Antiviral chemotherapy in children with respiratory syncytial virus infection. Antivir. Res. 61, 77–80.

Bridges, C., Harper, S., Fukuda, K., 2003. Prevention and control of influenza. J. Infect. Dis. 187, 1338–1341.

Bridges, C., Harper, S., Fukuda, K., 2003. Prevention and control of influenza. J. Infect. Dis. 187, 1338–1341.

Brooks, M.J., Sasadeusz, J.J., Tannock, G.A., 2004. Antiviral chemotherapy in children with respiratory syncytial virus infection. Antivir. Res. 61, 77–80.

Buckingham, S.C., Jafri, H.S., Bush, A.J., Carubelli, C.M., Sheeran, P., Hardy, J., 2001. Pre-emptive oral ribavirin therapy of paramyxovirus infections. Bone Marrow Transplant. 28, 759–763.

Bullock, P., Chen, N.Y., Wang, S.Y., 1999. Molecular epidemiology of adenovirus type 7 in the United States. Arch. Intern. Med. 163, 487–494.

Bullock, P., Chen, N.Y., Wang, S.Y., 1999. Molecular epidemiology of adenovirus type 7 in the United States. Arch. Intern. Med. 163, 487–494.
neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 347, 844–850.
Huygens, F.G., Atmar, R.L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Husson, L., Ward, P., Mills, R.G., 1999. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 342, 1336–1339.
Huygens, F.G., Gabrieli, J.V., Monto, A.S., Klein, T.C., Elliott, M.J., Hammond, J.M., Sharp, S.J., Osu, M.J., The Zanamivir Family Study Group. 2000. Initial zanamivir for the prevention of influenza in families. N. Engl. J. Med. 342, 1363–1369.
Huygens, F.G., Cump, C., Reece, P.A., Watson, K., Ryan, J., Cameron-Smith, R., Tucker, S.P., 2001. In vitro anti-rhinovirus spectrum and potency of BTA188, a novel, oral neuraminidase capsid/binder. Antivir. Res. 50, A75 (Abstract).
Huygen, F.P., Fields, P.B. 2002. Influenza Virus. In: Richman, D.D., Whitley, R.J., Hayden, F.G. (Eds.), Clinical Virology, 2nd ed. ASM Press, Washington, DC, pp. 890–920.
Huygen, F., Tamme, B., Gualavany, J.M., Chu-Burris, K., Gersten, M., Heys, P., Patick, A.K., Smith III, G.J., Zalman, L.S., 2003. Phase II, randomized, double-blind, placebo-controlled studies of repitative nasal spray 2- precent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antiviral Agents Chemotherapy, 47, 3907–3916.
Huygen, F.G., Belhaj, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Daikos, R., Ward, P., Core, P. 2003. Management of influenza in households: a prospective, randomized comparison of oral treatment with or without post-exposure prophylaxis. J. Infect. Dis. 188, 440–449.
He, M.L., Zhong, B., Peng, Y. 2003. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA, 290, 2655–2666.
Hedrick, J.A., Barzilai, A., Behe, U., Henderson, F.W., Hammond, J.A., Kozier, G. 2000. Zanamivir for treatment of symptomatic influenza A and B in children from twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 19, 410–417.
Henricson, J.K. 2003. Parainfluenza viruses. Clin. Microbiol. Rev. 16, 245–264.
Herscher, M.L., Carr, J., Ives, J., Eliau, S., Truscus, S., Roberts, N., Monto, A.S. 2002. Influenza virus carrying a HA292K mutation in the neuraminidase gene is not transmitted in ferrets. Arch. Virol. 54, 99–111.
Herholzer, J.C., 1992. Adenoviruses in the immunocompromised host. In vitro and in vivo activity of adenovirus ganciclovir against respiratory syncytial virus (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. U.S.A. 93, 2186–2191.
Hii, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C.R., 2004. Interactions with potent anti-influenza activity. J. Am. Chem. Soc. 119, 117–130.
Kaiser, L., Wat, C., Mills, T., Mahoney, T., Ward, P., Hayden, F.G. 2003. Impact of oseltamivir treatment of influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163, 1667–1672.
Kaplanulik, J., Os, R., Deluksina, M., Nagler, A., Lerni, N., Engelhardt, D. 1995. Intranasal ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. J. Pediatr. Gastroenterol. Nutr. 21, 110–112.
Kim, C., Lewis, W., Williams, M. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design synthesis and structural analysis of carbacylic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681–690.
Kiss, M., Mihara, K., Sakai-Tagawa, Y., Shirakawa, K., Kawai, C., Kimura, K., Hayden, F.G., Sugaya, N., Kawaoka, Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759–765.
Klimov, A.J., Rocha, E., Hayden, F.G., Shult, P.A., Roumiliat, L.F., Cox, N.J. 1995. Prolonged shedding of amantadine-resistance influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 172, 1352–1355.
Knoott, A.M., Long, C.E., Hall, C.B. 1994. Parainfluenza virus infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr. Infect. Dis. J. 13, 269–273.
Knowles, S.R., Philips, E.J., Drasar, L., Matukas, L., 2003. Common adverse events associated with use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. 37, 1139–1142.
Kosarik, T.G., Erdbom, D., Goldsmith, C.S., Zaki, S.R., Petri, T., Emery, S. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1955–1966.
Lamb, R., Webster, R. 2001. Orthomyxoviridae: the viruses and their replication. In: Kapec, D.M., Howley, P.M. (Eds.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp. 1487–1519.
Lambert, D.M., Barney, S., Lambert, A.L., Guthrie, K., Medina, R., Davis, D.E. 1996. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. U.S.A. 93, 2186–2191.
Lakruco, J., Campbell, J., Keene, O., Silagy, C. 2001. Zanamivir for treatment of influenza A and B in high-risk patients: a pooled analysis of randomized controlled trials. Arch. Intern. Med. 161, 212–217.
Le, Q.M., Kuo, M., Someya, K., Sakai, T.Y., Nguyen, T.H., Nguyen, K.H.L., Pham, N.D., Ngang, H.H., Yamada, S., Muramato, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y., Kawaoka, Y. 2005. Isolation of drug-resistant H5N1 virus. Nature 437, 1108.
Li, K.S., Guan, Y., Wang, J., Smith, G.J., Xu, K.M., Duan, L., Rahman, A.P., Pathavathulla, P., Bhatnath, C., Nguyen, T.D. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 433, 209–213.
Lin, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escolante, C.R. 2004. Interaction between leptotap repeat 1 and 2 regions in spike protein of SARS- associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 936–947.
Macklin, P.L. 2003. The classification of viruses infecting the respiratory tract. Pathol. Res. Rev. 4, 84–90.
Maggion, K., Bank, S. 2004. New drugs and treatment for respiratory syncytial virus. Rev. Med. Virol. 14, 189–186.
Makela, M.J., Puhakka, T., Raunela, O., Leeninen, M., Saikku, P., Kimpimaki, M. 1998. Viruses and bacteria in the etiology of the common cold. Clin. Microbiol. 36, 530–542.
Makela, M.J., Puhakka, K., Roethla, T., Fleming, D.M., Mann, C.Y., Keene, O.N., Webster, A. 2000. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized controlled trial. Chest. 118, 681–690.
Malinowski, M.D., Hostoffer, R.W. 2001. Home care based treatment with oseltamivir in the treatment of influenza virus infection in hematopoietic stem-cell transplant recipients. J. Pediatr. Gastroenterol. Nutr. 21, 110–112.
Martin, K., Heneisen, A. 1991. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 67, 117–130.
Preve, D.C., Tall, T.M., Serpel, M.E., Groucke, J.M., 1999. Activity of plecanaril against enteroviruses. Antimicrob Agents Chemother. 43, 2109–2115.

Preve, D.C., Hayden, F.G., Donnenzak, T.M., Barone, J.R., McKinlay, M.A., Collett, M.S., 2005. Relationship of plecanaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 49, 4492–4499.

The PREVENT Study Group, 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99, 93–99.

Price, G.A., Porter, D.D., 1996. Treatment of parainfluenza type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J. Infect. Dis. 173, 506–508.

Ribaud, P., Scuotto, C., Fremy, F., Montet, F., Gluckman, E., 1999. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin. Infect. Dis. 28, 690–691.

Reid, G., Frew, R., Thompson, J., Tollefsen, S., Wright, P.F., 1997. Epidemiology and clinical impact of parainfluenza virus infection in a healthy infant and young children <5 years old. J. Infect. Dis. 175, 807–813.

Roberts, N.A., 2001. Treatment of influenza with neuraminidase inhibitors: virological implications. Phil. Trans. Biol. Sci. 355, 1895–1897.

Roberts, H.A., O’Connell, J.F., McKinlay, M.A., 1998. Treatment of human enterovirus infections. Antivir. Res. 38, 1–14.

Roberts, H.A., 2000. Review: antiviral therapy for enteroviruses and rhinoviruses. Antivir. Chem. Chemother. 11, 261–271.

Rotbart, H.A., Meneu, O., Sakhlinen, H., 1985. Adenovirus diseases in children: a study of 105 cases. Pediatrics 76, 79–83.

Saito, R., Sakai, T., Sato, I., Sano, Y., Ohishi, H., Sato, M., Suzuki, H., 2003. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J. Microbiol. 41, 2164–2165.

Santonen, C., Blomqvist, S., Hort, T., 2003. Human rhinoviruses. Pediatr. Respir. Rev. 4, 91–98.

Schmid, A.C., Couch, B.B., Galasso, G.J., Hayden, F.G., Murphy, B.R., Chasnoff, R.N., 2001. Current research on respiratory viral infections. Antivir. Res. 50, 157–196.

Shigeru, S., 1998. Approaches to antiviral chemotherapy for acute respiratory infections. Infect. Chem. Ther. 9, 93–107.

Shirasaki, K., Mita, N., Kakinuma, K., Orito, K., Goto, H., Suga, N., Kawazaki, Y., 2003. High frequency of resistant viruses harboring different mutations in amantidine-treated children with influenza. J. Infect. Dis. 188, 57–61.

Sibaud, R.W., Sme, D.F., 2002. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Invest. Drugs 11, 859–869.

Sibaud, R.W., Bailey, K.W., Wong, M.H., Bamard, D.L., Sme, D.F., 2005. In vitro and in vivo influenza virus-inhibitory effects of valaciclovir. Antivir. Res. 68, 10–17.

Soman, R., Evans, M.J., 2001. Role of glucocorticosteroids in treating croup. Can. Fam. Physician 47, 733–735.

Stiver, G., 2003. The treatment of influenza with antiviral drugs. Can. Med. Assoc. J. 168, 48–56.

Sweet, C., Hayden, F.G., Jukema, K.J., Grambus, S., Huy, A.J., 1991. Virulence of rimantadine-resistant human influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2 in humans. J. Infect. Dis. 164, 169–172.

Trent, J.L., 2000. A family physician’s perspective on picornavirus infections in primary care. Arch. Fam. Med. 9, 921–922.

The M过错–RSV Study Group, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization for respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537.

Thiel, V., Hesford, J., Schall, B., Sapid, G., 2001. Influenza RNA transcribed in vitro from cDNA copy of the human coronavirus genome cloned in vaccinia virus. J. Gen. Virol. 82, 1273–1281.

Thompson, W.W., Shy, D.K., Weinsta, E., Brammer, L., Cox, N., Ander-son, L.J., Fukuda, K., 2003. Mortality associated with influenza and
respiratory syncytial virus. JAMA 289, 179–186.

Trenor, J.J., Hayden, F.G., Vreeman, P.S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kimberley, N., Ward, P., Mills, R.G., 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283, 1016–1024.

Tsai, P.T., Kowk, M.L., Yuen, H., Hai, S.T., 2003. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg. Infect. Dis. 9, 1604–1609.

Turner, R., Wecker, M., Pohl, G., Wiek, T.J., McNally, E., St George, R., Witek, T.J., McNally, E., St George, R., Turner, R., Wecker, M., Pohl, G., Witek, T.J., McNally, E., 1965. Cultivation of a novel common cold virus in organ cultures. BMJ 1, 1467–1470.

Van den Hoogen, B.G., de Jong, J.C., Groen, J., Kuiken, T., De Groot, R., 2005. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 353, 1677–1686.

Wagner, J.R., Hayden, F.G., Reissinger, K.S., Young, N., Dutkowski, R., Ipe, D., Mills, R.G., Ward, P., 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20, 127–133.

Wang, M.Z., Tai, C.Y., Mendel, D.B., 2002. Mechanism by which mutations in His274 after sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46, 469–475.

Wang, E., Sun, X., Qian, Y., Zhao, L., Tien, P., Gao, G.F., 2003. Both cellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 285, 748–754.

Wegner, S., Van, J.J., Liu, G., Byrn, P., Cypra, C., Campbell, W., Stiles, A., 2004. Direct cost analysis of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 114, 1612–1619.

Weinstock, D.M., Gabareva, L.V., Zacotti, G., 2003. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884–895.

Woo, P.C., Lau, S.K., Chu, C.M., Chan, K.H., Tsoi, H.W., Huang, Y., Wang, B.H., Poon, R.W., Cai, J.J., Luk, W.K., Poon, L.L., Wong, S.S., Guan, Y., Peiris, J.S., Yuan, K.Y., 2005a. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884–895.

Woo, P.C., Lau, S.K., Tsoi, H.W., Huang, Y., Poon, R.W., Chu, C.M., Lee, R.A., Luk, W.K., Wong, G.K., Wong, B.R., Cheng, V.C., Tang, B.S., Wai, A.K., Yang, R.W., Chen, H., Guan, Y., Chan, K.H., Yuan, K.Y., 2005b. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J. Infect. Dis. 192, 1898–1907.

Wright, P., Webster, R., 2001. Orthomyxoviruses. In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp. 1533–1562.

Wyde, P.R., Chetty, S.N., Jewell, A.M., Bowin, G., Piedra, P.A., 2003. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir. Res. 60, 51–59.

Wyde, P.R., Myllo, E.T., Chetty, S.N., Jewell, A.M., Bowin, G., Piedra, P.A., 2004. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMD03 in tissue culture assays. Antivir. Res. 63, 31–59.

Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Dever, H.W., Hassmann, G., Osaka, A., Tamamura, H., Fujii, N., Yamamoto, N., 2004. HIV protease inhibitor nefinivir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318, 719–725.

Yen, H.L., Monte, A.S., Webster, R.G., Gosinkova, E.A., 2005. Virulence may determine the necessary duration and dosage of oseltamivir treat- ment for highly pathogenic Avian influenza in mice. J. Infect. Dis. 192, 665–672.

Zhao, X., Singh, M., Malalovich, V.N., Kim, P.S., 2000. Structural charac- terization of the HRSV fusion protein core. Proc. Natl. Acad. Sci. U.S.A. 97, 14172–14177.

Zhu, M., 2004. SARS immunity and vaccination. Cell. Mol. Immunol. 1, 193–198.